Skip to main content

Table 6 Haplotype analysis of CD patients and non-IBD controls

From: Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease

Order

Haplotype a) b) c) d) e)

Cases (%)

Controls (%)

OR (C.I.)

P

Order

Haplotype a) b) c) d) e)

Cases (%)

Controls (%)

OR (C.I.)

P

1

G G A G G

258.6 (53.6)

511.2 (52.7)

1.04 (0.83-1.29)

 

1

G G A G G

265 (55.5)

530 (55.3)

1.01 (0.81-1.26)

a) ns

2

G G A G C

146.8 (30.5)

259.0 (26.7)

1.20 (0.95-1.53)

 

2

G G A G C

140 (29.4)

239 (24.9)

1.25 (0.98-1.60)

a) ns

3

G G A A C

39.3 (8.2)

93.9 (9.7)

0.83 (0.56-1.22)

 

3

G G A A C

44 (9.2)

110 (11.5)

0.79 (0.54-1.14)

a) ns

4

G G A A G

13 (2.7)

45.9 (4.7)

0.56 (0.30-1.04)

0.062

4

G G A A G

9 (1.9)

31 (3.2)

0.58 (0.27-1.22)

ns

5

A G A G G

2.1 (0.4)

14.4 (1.5)

0.29 (0.07-1.24)

0.053

5

A G A G G

1 (0.2)

13 (1.4)

0.15 (0.02-1.17)

0.044

6

A G A G C

3.9 (0.8)

11.6 (1.2)

0.68 (0.22-2.15)

 

6

A G A G C

5 (1)

14 (1.5)

0.72 (0.26-2.00)

ns

7

G G T G C

3.8 (0.8)

9.4 (1.0)

0.81 (0.24-2.68)

 

7

G G T G C

5

11

0.91 (0.32-2.65)

ns

8

G T A G G

2.1 (0.4)

7.8 (0.8)

0.53 (0.11-2.49)

NA

8

G T A G G

1 (0.2)

7 (0.7)

0.29 (0.04-2.33)

ns

9

G T A G C

6.1 (1.3)

5.7 (0.6)

2.19 (0.70-6.91)

0.122

9

G T A G C

7 (1.5)

6 (0.6)

2.37 (0.79-7.09)

ns

10

G G T G G

1.5 (0.3)

3.1 (0.3)

0.98 (0.14-6.86)

NA

10

G G T G G

1 (0.2)

2 (0.2)

1.01 (0.09-11.13)

ns

11

G T A A G

0

1.6 (0.2)

NA

NA

11

G T A A G

0

2 (0.2)

NA

ns

12

A G A A G

0

2.1 (0.2)

NA

NA

12

A G A A G

0

1 (0.1)

NA

ns

13

G G T A C

0.9 (0.2)

2.5 (0.3)

0.73 (0.07-7.9)

NA

13

G G T A C

0

2 (0.2)

NA

ns

14

G T T G C

3.1 (0.6)

0.9 (0.1)

NA

NA

14

G T T G C

3 (0.6)

1 (0.1)

6.07 (0.63-58.53)

ns

15

G G T A G

NA

NA

NA

NA

15

G G T A G

0

0

NA

NA

16

G T T A G

0.7 (0.1)

1.0 (0.1)

NA

NA

16

G T T A G

1 (0.2)

1 (0.1)

2.02 (0.13-32.30)

ns

17

A G A A C

NA

NA

NA

NA

17

A G A A C

0

0

NA

NA

18

A T A G C

NA

NA

NA

NA

18

A T A G C

0

0

NA

NA

19

G T T A C

NA

NA

NA

NA

19

G T T A C

0

0

NA

NA

  1. 241 cases (482 haplotypes) and 485 controls (970 haplotypes) were included in the analysis.
  2. Global haplotype distribution: P=0.079.
  3. Left table side: Predicted haplotype frequencies obtained with Monte Carlo simulations using FAMHAP: The calculation of odds ratios and a global P-value for haplotype distribution was performed on these results using FAMHAP. The haplotype order follows a priority ranking within the control group. Nineteen haplotypes were predicted. The haplotype base positions correspond to a) rs3863377, b) rs56163822, c) rs7138843, d) rs10860603, and e) rs35724. As FAMHAP tested all haplotypes with a frequency >0.01, the frequency distribution of eight haplotypes (1-7, 9) was included. Relevant P-values for three haplotypes were displayed by FAMHAP. None of the individual haplotypes are significantly differentially distributed between the CD and control groups. OR, odds ratio; NA, not applicable, FAMHAP did not calculate an odds ratio on these results because of a low haplotype frequency value predicted.
  4. Right table side (italics): Most likely occurring haplotype frequencies (haplotypes in best reconstruction) predicted by FAMHAP. Based on these predictions significance tests were performed.
  5. P-values were calculated using the Fisher’s exact test or (if marked with a) ) the Chi-Square-test. A Bonferroni-corrected P-value of 0.003 (19 tests) was taken as significance level. According to this, none of the haplotypes appeared to be significantly different distributed between the CD and control groups.
  6. OR, odds ratio; C.I., confidence interval; NA, OR not applicable because of at least one cell count with the value of null; ns, not significant and P > 0.05.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us